CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue, net	$ 6,652	$ 3,014	$ 23,139	$ 8,293
Operating expenses:
Costs of goods sold, including related party expenses of $266 and $121, respectively, and $926 and $332, respectively	3,616	2,763	13,315	7,584
Selling, general and administrative, including related party expenses of $126 and $124, respectively, and $376 and $369, respectively	17,032	24,725	87,188	50,642
Research and development, including related party expenses of $44 and $52, respectively, and $163 and $182, respectively	3,365	3,238	16,298	13,206
Amortization of intangible assets	567	567	1,700	1,700
Total operating expenses	24,580	31,293	118,501	73,132
Loss from operations	(17,928)	(28,279)	(95,362)	(64,839)
Change in the fair value of earnout liability	2,814		55,495
Change in the fair value of convertible promissory notes	(852)		(1,008)
Change in the fair value of warrants	540	(2,231)	6,624	(9,282)
Interest expense, net	(164)	(361)	(485)	(949)
Other income, net	1,441	141	2,371	1,032
Loss before income taxes	(14,149)	(30,730)	(32,365)	(74,038)
Provision for income taxes	0	0	0	17
Net loss	(14,149)	(30,730)	(32,365)	(74,055)
Accretion of Legacy Gelesis senior preferred stock to redemption value		(23,111)	(37,934)	(139,237)
Accretion of noncontrolling interest put option to redemption value	(80)	(95)	(253)	(285)
Net loss attributable to common stockholders	$ (14,229)	$ (53,936)	$ (70,552)	$ (213,577)
Net loss per share attributable to common stockholders - basic and diluted	$ (0.20)	$ (9.61)	$ (1.02)	$ (38.19)
Weighted average common shares outstanding - basic and diluted	72,772,627	5,615,192	69,349,679	5,592,931
Product Revenue, Net
Revenue:
Total revenue, net	$ 6,443	$ 3,014	$ 22,930	$ 8,293
Licensing Revenue
Revenue:
Total revenue, net	$ 209		$ 209